Literature DB >> 28007586

Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia.

David W Volk1.   

Abstract

Studies of genetics, serum cytokines, and autoimmune illnesses suggest that immune-related abnormalities are involved in the disease process of schizophrenia. Furthermore, direct evidence of cortical immune activation, including markedly elevated levels of many immune-related markers, have been reported in the prefrontal cortex in multiple cohorts of schizophrenia subjects. Within the prefrontal cortex in schizophrenia, deficits in the basilar dendritic spines of layer 3 pyramidal neurons and disturbances in inhibitory inputs to pyramidal neurons have also been commonly reported. Interestingly, microglia, the resident immune-related cells of the brain, also regulate excitatory and inhibitory input to pyramidal neurons. Consequently, in this review, we describe the cytological and molecular evidence of immune activation that has been reported in the brains of individuals with schizophrenia and the potential links between these immune-related disturbances with previously reported disturbances in pyramidal and inhibitory neurons in the disorder. Finally, we discuss the role that activated microglia may play in connecting these observations and as potential therapeutic treatment targets in schizophrenia.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dendritic spine; GABA; Immune; Inflammation; Inhibitory; Microglia; Prefrontal cortex

Mesh:

Year:  2016        PMID: 28007586      PMCID: PMC5303150          DOI: 10.1016/j.nbd.2016.12.019

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  115 in total

1.  Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.

Authors:  Lin Zhang; Yukihiko Shirayama; Masaomi Iyo; Kenji Hashimoto
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

2.  Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits.

Authors:  Masayuki Ide; David A Lewis
Journal:  Biol Psychiatry       Date:  2010-04-10       Impact factor: 13.382

3.  Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics.

Authors:  Teresa Wierzba-Bobrowicz; Eliza Lewandowska; Waldemar Lechowicz; Tomasz Stepień; Elzbieta Pasennik
Journal:  Folia Neuropathol       Date:  2005       Impact factor: 2.038

4.  A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia.

Authors:  A S Brown; P Cohen; J Harkavy-Friedman; V Babulas; D Malaspina; J M Gorman; E S Susser
Journal:  Biol Psychiatry       Date:  2001-03-15       Impact factor: 13.382

5.  Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA.

Authors:  Miran Kenk; Thiviya Selvanathan; Naren Rao; Ivonne Suridjan; Pablo Rusjan; Gary Remington; Jeffrey H Meyer; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

6.  Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.

Authors:  Dibyadeep Datta; Dominique Arion; John P Corradi; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-04-11       Impact factor: 13.382

7.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

Review 8.  Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Kazuto Oya; Taro Kishi; Nakao Iwata
Journal:  Hum Psychopharmacol       Date:  2014-09       Impact factor: 1.672

9.  Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia.

Authors:  Carlotta E Duncan; Maree J Webster; Debora A Rothmond; Sabine Bahn; Michael Elashoff; Cynthia Shannon Weickert
Journal:  J Psychiatr Res       Date:  2010-01-25       Impact factor: 4.791

10.  Genome-wide association study identifies five new schizophrenia loci.

Authors: 
Journal:  Nat Genet       Date:  2011-09-18       Impact factor: 38.330

View more
  17 in total

1.  Recapitulation and Reversal of Schizophrenia-Related Phenotypes in Setd1a-Deficient Mice.

Authors:  Jun Mukai; Enrico Cannavò; Gregg W Crabtree; Ziyi Sun; Anastasia Diamantopoulou; Pratibha Thakur; Chia-Yuan Chang; Yifei Cai; Stavros Lomvardas; Atsushi Takata; Bin Xu; Joseph A Gogos
Journal:  Neuron       Date:  2019-10-09       Impact factor: 17.173

Review 2.  Opportunities in precision psychiatry using PET neuroimaging in psychosis.

Authors:  Jennifer M Coughlin; Andrew G Horti; Martin G Pomper
Journal:  Neurobiol Dis       Date:  2019-03-20       Impact factor: 5.996

3.  Distinct Phenotypes of Inflammation Associated Macrophages and Microglia in the Prefrontal Cortex Schizophrenia Compared to Controls.

Authors:  Yunting Zhu; Maree J Webster; Caitlin E Murphy; Frank A Middleton; Paul T Massa; Chunyu Liu; Rujia Dai; Cyndi Shannon Weickert
Journal:  Front Neurosci       Date:  2022-06-30       Impact factor: 5.152

4.  The Role of the Nuclear Factor-κB Transcriptional Complex in Cortical Immune Activation in Schizophrenia.

Authors:  David W Volk; Annie E Moroco; Kaitlyn M Roman; Jessica R Edelson; David A Lewis
Journal:  Biol Psychiatry       Date:  2018-06-28       Impact factor: 13.382

5.  The morphometric co-atrophy networking of schizophrenia, autistic and obsessive spectrum disorders.

Authors:  Franco Cauda; Andrea Nani; Tommaso Costa; Sara Palermo; Karina Tatu; Jordi Manuello; Sergio Duca; Peter T Fox; Roberto Keller
Journal:  Hum Brain Mapp       Date:  2018-01-18       Impact factor: 5.038

Review 6.  Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases.

Authors:  Anne-Claire Dupont; Bérenger Largeau; Maria Joao Santiago Ribeiro; Denis Guilloteau; Claire Tronel; Nicolas Arlicot
Journal:  Int J Mol Sci       Date:  2017-04-07       Impact factor: 5.923

7.  ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis.

Authors:  S M Cotton; M Berk; A Watson; S Wood; K Allott; C F Bartholomeusz; C C Bortolasci; K Walder; B O'Donoghue; O M Dean; A Chanen; G P Amminger; P D McGorry; A Burnside; J Uren; A Ratheesh; S Dodd
Journal:  Trials       Date:  2019-11-28       Impact factor: 2.279

Review 8.  Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.

Authors:  Jason Smucny; Samuel J Dienel; David A Lewis; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2021-07-20       Impact factor: 7.853

Review 9.  Human Endogenous Retroviral Envelope Protein Syncytin-1 and Inflammatory Abnormalities in Neuropsychological Diseases.

Authors:  Xiuling Wang; Jin Huang; Fan Zhu
Journal:  Front Psychiatry       Date:  2018-09-07       Impact factor: 4.157

10.  Elevated serum chemokine CCL22 levels in first-episode psychosis: associations with symptoms, peripheral immune state and in vivo brain glial cell function.

Authors:  Heikki Laurikainen; Arja Vuorela; Anna Toivonen; Linnea Reinert-Hartwall; Kalevi Trontti; Maija Lindgren; Jaakko Keinänen; Teemu Mäntylä; Janina Paju; Tuula Ilonen; Reetta-Liina Armio; Maija Walta; Jouni Tuisku; Semi Helin; Päivi Marjamäki; Iiris Hovatta; Sebastian Therman; Outi Vaarala; Outi Linnaranta; Tuula Kieseppä; Raimo K R Salokangas; Jarno Honkanen; Jarmo Hietala; Jaana Suvisaari
Journal:  Transl Psychiatry       Date:  2020-03-16       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.